The Globe and Mail reports in its Friday, Feb. 6, edition that National Bank analyst Matt Kornack and Giuliano Thornhill continue to rate Extendicare "outperform," with an unchanged share target of $29. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $24. Mr. Kornack and Mr. Thornhill say in a note: "Extendicare moves to the top of our healthcare pecking order as we now set our target to a 6.5-per-cent FCF yield. Extendicare continues to progress toward a service-dominant platform; as such we expect valuation to transition towards FCF versus the former SOTP/NAV analysis. Extendicare currently trades at 8 per cent our 2027 FCFE versus roll-up plays covered by Zachary Evershed (ranging from 6 to 8 per cent), and its more asset heavy peers (Chartwell Retirement REIT mid-2 per cent and Sienna Senior Living REIT mid-4 per cent). To reach this 6.5-per-cent level, we anticipate successful integration of CBI Home Health, further execution of M&A and a resilient operating environment to endure."